Neuspera Medical said today that it raised a $26 million Series B round for the injectable neuromodulation devices it’s developing. Formerly known as Vivonda Medical, San Jose, Calif.-based Neuspera said the round was led by 6 Dimensions Capital, joined by all of its Series A investors, including Action Potential Venture Capital and Windham Venture Partners, and new […]
Funding Roundup
Gecko Biomedical wins $7m French grant for tissue reconstruction tech
Gecko Biomedical said today that it won a French grant worth roughly $7 million has (€6 million) for the tissue reconstruction technology it’s developing. Paris-based Gecko said it plans to use the grant to commercialize its portfolio of synthetic light-activated polymers, which are designed to be biocompatible and bioresorbable and act as an adhesive, barrier or filler […]
Aerie Pharmaceuticals prices $75m public offering
Aerie Pharmaceuticals (NSDQ:AERI) has priced an underwritten public offering of $75 million in shares of its common stock. The Irvine, Calif.-based company also plans to grant underwriters a 30-day option to buy up to $11.3 million in shares of common stock. Get the full story at our sister site, Drug Delivery Business News.
These medtech companies raised the most VC last year
Perhaps there’s a ray of hope that venture capital funding is recovering a bit for the medical device industry. VC firms invested more than $2.8 billion in 2017, an increase of more than $647 million from 2016, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and CB Insights. There were a total 229 deals involving […]
Centinel Spine reports $132m funding round
Fresh from its acquisition of Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Prodisc assets, Centinel Spine last week reported raising more than $132 million. In the waning days of 2017, Centinel it closed its acquisition of DePuy’s Prodisc-C, Prodisc-L, Prodisc-C Vivo, Prodisc-C Nova, Prodisc-O and Discover cervical and lumbar artificial disc systems. Although the purchase price remained undisclosed, Centinel said at […]
Pavmed prices $4.3m offering
Pavmed (NSDQ:PAVM) today priced an underwritten public offering of 2,415,278 shares of its common stock at $1.80 per share. The New York City-based company said it would grant the offering’s underwriters a 45-day option to buy up to 362,292 additional shares of common stock to cover over-allotments. Pavmed expects to bring in $3.9 million in net […]
Obalon preps $35m offering
Obalon Therapeutics (NSDQ:OBLN) said this week that it’s planning a share flotation worth $35 million that could swell by another $5 million if an over-allotment option is fulfilled. The San Diego-based medical device company won pre-market approval from the FDA for its ingestible, gas-filled weight-loss balloon in September 2016. The Obalon device is indicated for weight loss in adults 30 to […]
Pavmed registers $90m offering
Pavmed (NSDQ:PAVM) has registered for a nearly $90 million offering, saying it plans to float the rights to buy up to 14.6 million units. The New York City-based company said it would issue a single unit for each share of common stock. Each unit is slated to include one common share and a six-year Series Z warrant worth […]
Pavmed sets terms for warrants offering
Pavmed (NSDQ:PAVM) said today that it set the terms for a forthcoming rights offering, saying it plans to issue a single unit for each share of common stock. Each unit will include one common share and a six-year Series Z warrant worth $2.25 per share, redeemable at $3 each, the New York City-based company said. Last […]
BioAdvance drops $3.2m on device, drug bets
Early-stage life science fund BioAdvance announced that it has added an array of new companies to its portfolio, investing nearly $3.2 million into companies from the mid-Atlantic region of the U.S. Two of the firm’s largest investments went to Opsidio, a Bryn Mawr, Penn.-based company developing monoclonal antibodies to treat fibrotic diseases, and New York-based Pillo Health, […]
Siemens Healthineers to cut costs by $290m ahead of IPO
Siemens (NYSE:SI) said today that it plans to shave more that $290 million from the cost of running its Healthineers business, ahead of a pending initial public offering that could fetch nearly $50 billion. Late last year, the German industrial conglomerate said it plans to list 15% to 25% of the its largest and most profitable business on […]